Best Fibroscan doctors in Barcelona: TOP 2 doctors

A specialist in the digestive system through MIR from the Hospital Clinic of Barcelona and a Doctor of Medicine from the University of Barcelona, he received his PhD from the University of Barcelona.

He completed his postgraduate training in the Gastroenterology Service of the Barcelona Hospital Clinic and then in the Department of Gastroenterology at Case Western Reserve University (Cleveland, USA), where he conducted cutting-edge research on inflammatory bowel diseases (IBD, Crohn's disease and ulcerative colitis).

From 2004 to 2011 he worked in the Gastroenterology Department of the Barcelona Hospital Clinic / IDIBAPS, and since 2011 he has worked as a specialist doctor in the Digestive System Department of the Teknon Medical Center in Barcelona.

He was a member of the Scientific Committee of ECCO and coordinator of the European project "IBDChip". He is the author of more than 150 publications and 500 presentations at conferences and conferences.

Experience:

Digestive system specialist, completed the MIR training program and completed his residency in this specialty at the Provincial Hospital of Barcelona between 1993 and 1996.

Doctor of Medicine from the University of Barcelona with the qualification "Distinguished Diploma Unanimously". In 2001 he received the Distinguished Doctorate from the University of Barcelona.

Between 1997 and 1999, he completed his postgraduate training in the Gastroenterology Department of the Provincial Hospital of Barcelona. Subsequently, he completed two internships in the Gastroenterology Department of Case Western Reserve University in Cleveland, USA, between 2000 and 2003, where he conducted cutting-edge research in the field of gastroenterology.

Since 2004 he has been working in the Gastroenterology Service of the Provincial Hospital of Barcelona / IDIBAPS, focusing on the treatment and research of inflammatory bowel diseases.

He is the author of numerous publications, conference papers and book chapters both nationally and internationally.

Member of the Catalan Society of Gastroenterology, the Spanish Association of Gastroenterology, the Spanish Working Group on Crohn's Disease and Ulcerative Colitis and the American Gastroenterological Association.

Areas of special interest: storage rhythm disorders, chronic diarrhea, inflammatory bowel diseases (Crohn's disease and ulcerative colitis) and other causes of chronic intestinal inflammation.

Dr. Sullivan graduated in Medicine and Surgery from the National University of Rosario in 2005, specializing in Medical Oncology through the MIR at the Santa Creu i Sant Pau Hospital (HSCiSP, 2012) in Barcelona.

She received a post-MIR scholarship from the Ministry of Interior from HSPiSP (2012) and then a pre-doctoral scholarship from ISCiii (Rio Hortega – 2013-2015).

In 2014, he moved to Paris where he obtained a DUERTECC diploma at the Gustave Roussy University Hospital (Villejuif), followed by an ESMO scholarship (Georges Mathé Translator Scholarship), which he received in 2016.

Since January 2017, he has been working on the staff of the Medical Oncology Department of the HSCiSP. In the same year, he obtained his PhD from the Autonomous University of Barcelona.

Since 2015, he has been a member of the Board of Directors of the Spanish Lung Cancer Group (GECP). And since 2022, he has been the coordinator of the HSCiSP Committee on Neuroendocrine Tumors.

In November 2021, she joined the IOR Medical Oncology Service and is actively involved in various research projects in the Pangea Lab under the supervision of Dr. Molina.

Dr. Sullivan is involved in several clinical trials in lung cancer and neuroendocrine tumors, many of which have been presented at various international scientific meetings.

She has participated in national and international conferences and is an author and co-author of research articles published in influential journals.

She is currently a member of the Spanish Society of Medical Oncology (SEOM), GECP, European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).